Engin Ayturk

Executive Director, CMC Process Engineering and BioConjugation Development

Engin Ayturk, is an Executive Director at Mersana Therapeutics, leading the CMC Process Engineering and BioConjugation departments and responsible for the development, scale-up and cGMP manufacturing, late-stage characterization and validation of novel antibody drug conjugate (ADC) technology platforms. Previously at Biogen, Dr. Ayturk led the Cambridge Process Biochemistry (PBC) small and pilot scale purification and bioseparation development teams and was responsible for the development of purification processes for clinical and commercial biologics programs. During his tenure at Pall Life Sciences, as a Sr. R&D Manager, Dr. Ayturk led the BioPharm Applications R&D Integrated Continuous BioProcessing team and the Filtration Groups for the development and commercialization of next generation novel bioprocess platforms and technologies. In addition to his primary focus on product, process and technology development, characterization, scale-up and tech transfer and cGMP manufacturing, Dr. Ayturk brings a strong emphasis on process modeling, bioprocess economics and the development of process control strategies for various technologies and is well recognized for cross-functional team leadership, internal/external collaborations and partnerships, and CDMO/CMO management and has numerous business certifications on project and people management, agile product development and innovation coaching modules. Dr. Ayturk holds M.Sc. and Ph.D. degrees both in Chemical Engineering and previously worked as a Research Assistant Professor at Worcester Polytechnic Institute (WPI).

Talks About
#chemicalengineering #rd

Preferred Locations
#NorthAmerica